Baxalta
Also known as: Baxalta GmbH | Baxalta Innovations GmbH | Baxalta Japan Limited | Baxalta, now part of Shire | Baxalta US Inc. | Baxter | Baxter BioScience | Baxter (China) Investment Co. Ltd. | Baxter Deutschland GmbH | Baxter Healthcare | Baxter Healthcare Corporation | Baxter Healthcare International | BAXTER HLTHCARE CORP | Baxter Innovations GmbH
Highest phase reached
Phase 4
First clinical trial
Apr 1, 1997First marketed drug
Mar 22, 1950First NDA
Nov 16, 1959Last known activity
Jan 27, 2025
Timeline
1930s
- Jan 1, 1931
Baxalta— Founded
1950s
- Apr 13, 1956
promazine hydrochloride— NDA Secondary Org
1970s
- Aug 24, 1979
hydroxyzine— Marketing Organization
1980s
- Jan 1, 1986
American Hospital Supply— Acquired
- Jan 1, 1986
Ascot Pharmaceuticals— Acquired
1990s
- Jan 1, 1993
Anaquest— Acquired
- Jun 1, 1997
Immuno US, Inc.— Acquired
- Jan 1, 1999
Immuno AG— Acquired
- Jan 1, 1999
2000s
- Dec 20, 2002
icodextrin— NDA Organization
2010s
- Jan 1, 2010
Apatech— Acquired
- Nov 19, 2010
Archemix Corp.— Acquired
- Jan 1, 2011
Prism Research— Acquired
- Jan 1, 2013
Flowsense— Acquired
- Jan 1, 2013
Gambro— Acquired
- Jan 1, 2014
AesRx— Acquired
- Jan 1, 2014
Chatham Therapeutics— Acquired
- Jan 1, 2015
SuppreMol— Acquired
- Jun 3, 2016
Shire— Acquired By
- Dec 3, 2018
Takeda— Now
Drugs by trial phase (143 distinct, 273 trials)
Phase 4 (32 own, 1 via acquisition)
Phase 3 (43 own, 4 via acquisition)
- urea
- mercaptopurine
- dasatinib
- antihemophilic factor viii (Recombinant), porcine sequence
- acetaminophen
- drotrecogin alfa, activated
- conjugated linoleic acid
- von Willebrand factor (recombinant)
- tranexamic acid
- inactivated influenza vaccine
- pegaspargase
- cyclosporine
- naltrexone
- hepatitis b vaccine (recombinant)
- cytarabine
- +32 more
Phase 2 (19 own, 13 via acquisition)
Phase 1 (12 own, 15 via acquisition)
Other trials (3 own, 1 via acquisition)
Indications
Approved for
Studied for
- Acute Kidney Injury
- Adenocarcinoma
- Agammaglobulinemia
- alpha 1-Antitrypsin Deficiency
- Alzheimer Disease
- Anemia, Sickle Cell
- Angina Pectoris
- Aortic Valve Stenosis
- Arthritis
- Arthritis, Rheumatoid
- Ascites
- Ataxia
- Autoimmune Diseases
- Autoimmune Diseases of the Nervous System
- Bile Duct Neoplasms
- Biliary Tract Neoplasms
- Bone Diseases
- Borrelia Infections
- Burns
- Calculi
- Carcinoma
- Carcinoma, Ductal
- Carcinoma, Hepatocellular
- Carcinoma, Ovarian Epithelial
- Carcinoma, Squamous Cell
- Cerebellar Ataxia
- Cerebral Hemorrhage
- Cerebrospinal Fluid Leak
- Cognitive Dysfunction
- Colorectal Neoplasms
- Coronary Artery Disease
- Coronary Disease
- Cystic Fibrosis
- Dehydration
- Delayed Emergence from Anesthesia
- Delayed Graft Function
- Delirium
- Diabetes Mellitus, Type 1
- Disease Progression
- Emergencies
- Encephalitis
- Encephalitis, Tick-Borne
- Epilepsies, Partial
- Epilepsy
- Esophageal and Gastric Varices
- Fibrosis
- Glomerulonephritis, IGA
- Graft vs Host Disease
- Heart Diseases
- Heart Failure
- Hematoma
- Hemophilia A
- Hemophilia B
- Hemorrhage
- Hepatitis B
- Hernia
- Hypersensitivity
- Hypertension
- Hypertriglyceridemia
- Hypovolemia
- Immunologic Deficiency Syndromes
- Incisional Hernia
- Influenza, Human
- Influenza in Birds
- Insulin Resistance
- Ischemia
- Kidney Diseases
- Kidney Failure, Chronic
- Leukemia
- Leukemia, Lymphoid
- Limbic Encephalitis
- Lung Diseases
- Lung Diseases, Obstructive
- Lupus Erythematosus, Systemic
- Lupus Nephritis
- Lymphoma
- Lymphoma, Non-Hodgkin
- Malnutrition
- Melanoma
- Meningitis
- Meningitis, Meningococcal
- Metabolic Diseases
- Mucocutaneous Lymph Node Syndrome
- Myocardial Ischemia
- Neoplasms
- Nephritis
- Nervous System Diseases
- Neuritis
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Pathologic Processes
- Periodontitis
- Peripheral Arterial Disease
- Peripheral Vascular Diseases
- Pneumonia
- Polycythemia Vera
- Polyradiculoneuropathy
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Postoperative Pain
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
Marketed drugs (125)
Subsidiaries (14 direct, 15 total across the full acquisition tree)
Recent trials (50)
- NCT06842134OfficialPhase 1Jan 27, 2025
- NCT06842121OfficialPhase 1Jan 27, 2025
- NCT06842121Lead sponsorPhase 1Jan 27, 2025
- NCT06842134Lead sponsorPhase 1Jan 27, 2025
- NCT05721404CollaboratorPhase 4May 24, 2023
- NCT05490940CollaboratorN/AJan 1, 2023
- NCT05399537Lead sponsorPhase 3Nov 30, 2022
- NCT05567601Lead sponsorPhase 1Nov 14, 2022
- NCT05309304Lead sponsorPhase 1Feb 14, 2022
- NCT04555044Lead sponsorPhase 4Nov 19, 2020
- NCT04555044Study directorPhase 4Nov 19, 2020
- NCT04155814Lead sponsorPhase 1Oct 15, 2019
- NCT04094038CollaboratorPhase 4Sep 30, 2019
- NCT04083807Lead sponsorPhase 3Jul 10, 2019
- NCT03477344CollaboratorPhase 3Jun 30, 2018
Details
- Founded
- Deerfield, IL, US Jan 1, 1931
- First NDA
- Nov 16, 1959
- Last known activity
- Jan 27, 2025
Designations held
- Orphan drug
- Priority review
Notes
--- Pre-folding founded info: 2015-01-01 Bannockburn IL US https://www.crunchbase.com/organization/baxalta#/entity ---